Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 49, Issue 12, 2008, Pages 2359-2364

  Ishikawa, Yuichi ^a   Xu, Jinglan ^a   Sakashita, Gyosuke ^b   Urano, Takeshi ^b   Suzuki, Tatsuya ^a   Tomita, Akihiro ^a   Kiyoi, Hitoshi ^c   Nakamura, Shigeo ^c   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Immunohistochemical staining; Myelodysplastic syndrome; Nucleophosmin

Indexed keywords

MESSENGER RNA; NUCLEAR PROTEIN; NUCLEOPHOSMIN 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; CELLULAR DISTRIBUTION; CHROMOSOME 5; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

BONE MARROW; CHROMOSOME ABERRATIONS; CYTOPLASM; DISEASE PROGRESSION; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; RNA, MESSENGER;

EID: 57449085910     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802541815     Document Type: Article

References (23)

1. Korgaonkar, C., Hagen, J., Tompkins, V., Frazier, A. A., Allamargot, C. Quelle, F. W. et al. (2005) Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol, 25, pp. 1258-1271.
2. Kurki, S., Peltonen, K., Latonen, L., Kiviharju, T. M., Ojala, P. M. Meek, D. et al. (2004) Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell, 5, pp. 465-475.
3. Colombo, E., Marine, J. C., Danovi, D., Falini, B. and Pelicci, P. G. (2002) Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol, 4, pp. 529-533.
4. Borer, R. A., Lehner, C. F., Eppenberger, H. M. and Nigg, E. A. (1989) Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell, 56, pp. 379-390.
5. Chan, W. Y., Liu, Q. R., Borjigin, J., Busch, H., Rennert, O. M. Tease, L. A. et al. (1989) Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry, 28, pp. 1033-1039.
6. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R. Pasqualucci, L. et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med, 352, pp. 254-266.
7. Grisendi, S., Mecucci, C., Falini, B. and Pandolfi, P. P. (2006) Nucleophosmin and cancer. Nat Rev Cancer, 6, pp. 493-505.
8. Naoe, T., Suzuki, T., Kiyoi, H. and Urano, T. (2006) Nucleophosmin: A versatile molecule associated with hematological malignancies. Cancer Sci, 97, pp. 963-969.
9. Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N. Look, A. T. et al. (1995) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science, 267, pp. 316-317.
10. Yoneda-Kato, N., Look, A. T., Kirstein, M. N., Valentine, M. B., Raimondi, S. C. Cohen, K. J. et al. (1996) The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene, 12, pp. 265-275.
11. Redner, R. L., Rush, E. A., Faas, S., Rudert, W. A. and Corey, S. J. (1996) The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood, 87, pp. 882-886.
12. Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T. Schaich, M. et al. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 107, pp. 4011-4020.
13. Verhaak, R. G., Goudswaard, C. S., van Putten, W., Bijl, M. A., Sanders, M. A. Hugens, W. et al. (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood, 106, pp. 3747-3754.
14. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C. Martelli, M. F. et al. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, pp. 3733-3739.
15. Dohner, K., Schlenk, R. F., Habdank, M., Scholl, C., Rucker, F. G. Corbacioglu, A. et al. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood, 106, pp. 3740-3746.
16. Suzuki, T., Kiyoi, H., Ozeki, K., Tomita, A., Yamaji, S. Suzuki, R. et al. (2005) Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood, 106, pp. 2854-2861.
17. Grisendi, S., Bernardi, R., Rossi, M., Cheng, K., Khandker, L. Manova, K. et al. (2005) Role of nucleophosmin in embryonic development and tumorigenesis. Nature, 437, pp. 147-153.
18. Berger, R., Busson, M., Baranger, L., Helias, C., Lessard, M. Dastugue, N. et al. (2006) Loss of the NPM1 gene in myeloid disorders with chromosome 5 rearrangements. Leukemia, 20, pp. 319-321.
19. Oki, Y., Jelinek, J., Beran, M., Verstovsek, S., Kantarjian, H. M. and Issa, J. P. (2006) Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica, 91, pp. 1147-1148.
20. Ozeki, K., Kiyoi, H., Hirose, Y., Iwai, M., Ninomiya, M. Kodera, Y. et al. (2004) Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood, 103, pp. 1901-1908.
21. Xu, J. L., Lai, R., Kinoshita, T., Nakashima, N. and Nagasaka, T. (2002) Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: Correlation with the clinical stage and cytological grade. J Clin Pathol, 55, pp. 530-534.
22. Corey, S. J., Minden, M. D., Barber, D. L., Kantarjian, H., Wang, J. C. and Schimmer, A. D. (2007) Myelodysplastic syndromes: The complexity of stem-cell diseases. Nat Rev Cancer, 7, pp. 118-129.
23. Sportoletti, P., Grisendi, S., Majid, S. M., Cheng, K., Clohessy, J. G. Viale, A. et al. (2008) Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood, 111, pp. 3859-3862.